PTGX Relative Valuation
PTGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTGX is overvalued; if below, it's undervalued.
Historical Valuation
Protagonist Therapeutics Inc (PTGX) is now in the Fair zone, suggesting that its current forward PS ratio of 25.03 is considered Fairly compared with the five-year average of -18.42. The fair price of Protagonist Therapeutics Inc (PTGX) is between 38.26 to 181.68 according to relative valuation methord.
Relative Value
Fair Zone
38.26-181.68
Current Price：80.10
Fair
80.32
PE
1Y
3Y
5Y
63.36
EV/EBITDA
Protagonist Therapeutics Inc. (PTGX) has a current EV/EBITDA of 63.36. The 5-year average EV/EBITDA is 19.79. The thresholds are as follows: Strongly Undervalued below -252.06, Undervalued between -252.06 and -116.13, Fairly Valued between 155.72 and -116.13, Overvalued between 155.72 and 291.65, and Strongly Overvalued above 291.65. The current Forward EV/EBITDA of 63.36 falls within the Historic Trend Line -Fairly Valued range.
-73.46
EV/EBIT
Protagonist Therapeutics Inc. (PTGX) has a current EV/EBIT of -73.46. The 5-year average EV/EBIT is -1.72. The thresholds are as follows: Strongly Undervalued below -145.23, Undervalued between -145.23 and -73.48, Fairly Valued between 70.04 and -73.48, Overvalued between 70.04 and 141.80, and Strongly Overvalued above 141.80. The current Forward EV/EBIT of -73.46 falls within the Historic Trend Line -Fairly Valued range.
25.03
PS
Protagonist Therapeutics Inc. (PTGX) has a current PS of 25.03. The 5-year average PS is 40.86. The thresholds are as follows: Strongly Undervalued below -15.17, Undervalued between -15.17 and 12.85, Fairly Valued between 68.88 and 12.85, Overvalued between 68.88 and 96.89, and Strongly Overvalued above 96.89. The current Forward PS of 25.03 falls within the Historic Trend Line -Fairly Valued range.
26.42
P/OCF
Protagonist Therapeutics Inc. (PTGX) has a current P/OCF of 26.42. The 5-year average P/OCF is 24.21. The thresholds are as follows: Strongly Undervalued below -286.29, Undervalued between -286.29 and -131.04, Fairly Valued between 179.46 and -131.04, Overvalued between 179.46 and 334.71, and Strongly Overvalued above 334.71. The current Forward P/OCF of 26.42 falls within the Historic Trend Line -Fairly Valued range.
36.86
P/FCF
Protagonist Therapeutics Inc. (PTGX) has a current P/FCF of 36.86. The 5-year average P/FCF is 33.61. The thresholds are as follows: Strongly Undervalued below -253.70, Undervalued between -253.70 and -110.05, Fairly Valued between 177.26 and -110.05, Overvalued between 177.26 and 320.91, and Strongly Overvalued above 320.91. The current Forward P/FCF of 36.86 falls within the Historic Trend Line -Fairly Valued range.
Protagonist Therapeutics Inc (PTGX) has a current Price-to-Book (P/B) ratio of 8.43. Compared to its 3-year average P/B ratio of 4.65 , the current P/B ratio is approximately 81.38% higher. Relative to its 5-year average P/B ratio of 4.27, the current P/B ratio is about 97.55% higher. Protagonist Therapeutics Inc (PTGX) has a Forward Free Cash Flow (FCF) yield of approximately 1.17%. Compared to its 3-year average FCF yield of -0.94%, the current FCF yield is approximately -223.85% lower. Relative to its 5-year average FCF yield of -5.94% , the current FCF yield is about -119.69% lower.
8.43
P/B
Median3y
4.65
Median5y
4.27
1.17
FCF Yield
Median3y
-0.94
Median5y
-5.94
Competitors Valuation Multiple
The average P/S ratio for PTGX's competitors is 7.30, providing a benchmark for relative valuation. Protagonist Therapeutics Inc Corp (PTGX) exhibits a P/S ratio of 25.03, which is 242.8% above the industry average. Given its robust revenue growth of 0.79%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PTGX increased by 117.83% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 60.67 to 121.05.
The secondary factor is the Margin Expansion, contributed 17.53%to the performance.
Overall, the performance of PTGX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
PLUS
ePlus inc
85.89USD
-0.49%
APGE
Apogee Therapeutics Inc
77.47USD
-1.87%
PHIN
Phinia Inc
67.97USD
2.52%
CCU
Compania Cervecerias Unidas SA
13.79USD
2.30%
IBRX
Immunitybio Inc
2.245USD
2.05%
KAR
Openlane Inc
30.88USD
0.36%
CMBT
CMB.TECH NV
11.28USD
6.62%
TRMK
Trustmark Corp
40.48USD
1.56%
SYBT
Stock Yards Bancorp Inc
67.81USD
3.20%
Frequently Asked Questions
Is Protagonist Therapeutics Inc (PTGX) currently overvalued or undervalued?
Protagonist Therapeutics Inc (PTGX) is now in the Fair zone, suggesting that its current forward PS ratio of 25.03 is considered Fairly compared with the five-year average of -18.42. The fair price of Protagonist Therapeutics Inc (PTGX) is between 38.26 to 181.68 according to relative valuation methord.
What is Protagonist Therapeutics Inc (PTGX) fair value?
PTGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Protagonist Therapeutics Inc (PTGX) is between 38.26 to 181.68 according to relative valuation methord.
How does PTGX's valuation metrics compare to the industry average?
The average P/S ratio for PTGX's competitors is 7.30, providing a benchmark for relative valuation. Protagonist Therapeutics Inc Corp (PTGX) exhibits a P/S ratio of 25.03, which is 242.80% above the industry average. Given its robust revenue growth of 0.79%, this premium appears unsustainable.
What is the current P/B ratio for Protagonist Therapeutics Inc (PTGX) as of Jan 08 2026?
As of Jan 08 2026, Protagonist Therapeutics Inc (PTGX) has a P/B ratio of 8.43. This indicates that the market values PTGX at 8.43 times its book value.
What is the current FCF Yield for Protagonist Therapeutics Inc (PTGX) as of Jan 08 2026?
As of Jan 08 2026, Protagonist Therapeutics Inc (PTGX) has a FCF Yield of 1.17%. This means that for every dollar of Protagonist Therapeutics Inc’s market capitalization, the company generates 1.17 cents in free cash flow.
What is the current Forward P/E ratio for Protagonist Therapeutics Inc (PTGX) as of Jan 08 2026?
As of Jan 08 2026, Protagonist Therapeutics Inc (PTGX) has a Forward P/E ratio of 80.32. This means the market is willing to pay $80.32 for every dollar of Protagonist Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Protagonist Therapeutics Inc (PTGX) as of Jan 08 2026?
As of Jan 08 2026, Protagonist Therapeutics Inc (PTGX) has a Forward P/S ratio of 25.03. This means the market is valuing PTGX at $25.03 for every dollar of expected revenue over the next 12 months.